Clinical Trials
10 trialsNCT03317392 2026-05-20
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02484404 2026-05-06
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT01116648 2026-05-04
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05933265 2026-05-04
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
Phase 1/2 Active not recruiting
NCT02734004 2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2 Active not recruiting
NCT03085147 2026-02-12
A Dye for the Detection of Cancer of the Tongue and Mouth
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT04728230 2025-12-18
Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03212742 2025-12-04
OLA-TMZ-RTE-01
Centre Francois Baclesse
Phase 1/2 Active not recruiting
NCT02571725 2025-05-23
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
New Mexico Cancer Research Alliance
Phase 1/2 Active not recruiting
NCT03594396 2025-04-17
Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer
Seoul National University Hospital
Phase 1/2 Active not recruiting